Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.

View Full Paper
Ask AI
Bookmark
Share

Authors

TCThomas CluzeauCentre National de la Recherche ScientifiqueCBClaire BoriesCentre Hospitalier de LensRRRamy RahméSorbonne Université

Discussion

Loading...

Member takes

Overview

Observational study reports poor overall survival and treatment decisions influenced by TP53 mutations in AML.

Key Points

  • To explore real-world management and outcomes in adults with TP53-mutated acute myeloid leukemia (AML).
  • Analyzed data from the ALFA-PPP registry including 1,108 newly diagnosed AML patients
  • Conducted genomic profiling focusing on TP53 mutations
  • Utilized multivariable analysis for survival outcomes with logistic and Cox regression
  • 165 patients had TP53 mutations at diagnosis
  • Median overall survival was 11.7 months for intensive treatment and 4.8 months for less intensive
  • TP53 mutations were linked to less intensive treatment options (OR, 6.5)

Cite This Study

Cluzeau et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5achttps://doi.org/10.1182/blood-2025-6386
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations
  2. 2Real-world outcomes of TP53-mutated acute myeloid leukemia at a single institution.2026
  3. 3Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation2026
  4. 4Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation2025
  5. 5<i>TP53</i> variant allele frequency as a driver of survival in <i>TP53</i> -mutated acute myeloid leukemia.2026